Metabolomics in urogenital cancer

Bioanalysis

Volumn 3, Issue 8, 2011, Pages 913-923

  Bujak, Renata ^a   Daghir, Emilia ^a   Rybka, Joanna ^a   Koslinski, Piotr ^a   Markuszewski, Michał Jan ^a,b  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANALYTIC METHOD; CAPILLARY ZONE ELECTROPHORESIS; CARBON NUCLEAR MAGNETIC RESONANCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTERMETHOD COMPARISON; MASS FRAGMENTOGRAPHY; METABOLOMICS; MOLECULAR PATHOLOGY; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SEPARATION TECHNIQUE; UROGENITAL TRACT CANCER;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; METABOLOME; METABOLOMICS; TUMOR MARKERS, BIOLOGICAL; UROGENITAL NEOPLASMS;

EID: 79955371143     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.11.43     Document Type: Review

References (58)

1. Spratlin JL, Serkova NJ, Ekhardt SG. Clinical applications of metabolomics in oncology: a review. Clin. Cancer Res. 15, 431-440 (2009).
2. Van QV, Veenstra TD. How close is the bench to the bedside? Metabolic profiling in cancer research. Genome Medicine 5, 1-6 (2009).
3. Ma Y, Liu G, Du M et al. Recent development in the determination of urinary cancer biomarkers by capillary electrophoresis. Electrophoresis 25, 1473-1484 (2004). (Pubitemid 38885806)
4. Melichar B, Solichova D, Svobodova I et al. Neopterin in renal cell carcinoma inhalational administration of interleukin-2 is not accompanied by a rise of urinary neopterin. Luminescence 20, 310-314 (2005).
5. Seidel A, Brunner S, Seidel P et al. Modified nucleosides: an accurate tumor marker for clinical diagnosis of cancer, early detection therapy control. Br. J. Cancer. 94, 1726-1733 (2006). (Pubitemid 43924939)
6. Byun JA, Lee SH, Choi MH et al. Analysis of polyamines as carbamonyl derivaties in urine and serum by liquid chromatography-tandem mass spectrometry. Biomed. Chromatogr. 22, 73-80 (2008). (Pubitemid 351176046)
7. Szymańska E, Markuszewski MJ, Markuszewski M, Kaliszan R. Altered levels of nucleoside metabolite profiles in urogenital tract cancer measured by capillary electrophoresis J. Pharm. Biomed. Anal. 53, 1305-1312 (2010).
8. Denkart C, Budczeis J, Kind T et al. Mass spectrometry-based metabolic profiling reveals. Different metabolite patterns in invasiwe ovarian carcinomas and ovarian borderline tumors. Cancer Res. 66, 10795-10804 (2006). (Pubitemid 44876975)
9. Kind T, Tolstikov V, Fiehn O et al. A comprehensive urinary metabolomic approaches for identifying kidney. Cancer Anal. Biochem. 363, 185-195 (2007). (Pubitemid 46428214)
10. Ramautar R, Somsen GW, de Jong GJ. CE-MS in metabolomics. Electrophoresis 30(1), 276-291 (2009).
11. Monton MRN, Soga T. Metabolome analysis by capillary electrophoresis-mass spectrometry. J. Chromatogr. A 1168(1-2), 237-246 (2007). (Pubitemid 47488321)
12. Lindon JC, Holmes E, Bollard ME, Stanley EG, Nicholson JK. Metabonomics technologies and their applications in physiological monitoring, and drug safety assessment and disease diagnosis. Biomarkers 9(1), 1-31 (2004). (Pubitemid 38660013)
13. Shockcor JP, Holmes E. Metabonomic applications in toxicity screening and disease diagnosis. Curr. Top. Med. Chem. 2(1), 35-51 (2002).
14. Lenz EM, Wilson ID. Analytical strategies in metabonomics. J. Proteome Res. 6(2), 443-458 (2007). (Pubitemid 46340149)
15. Coen M. A metabonomic approach for mechanistic exploration of pre-clinical toxicology. Toxicology 278(3), 326-340 (2010).
16. Dunn WB, Bailey NJC, Johnson HE. Measuring the metabolome: current analytical technologies. Analyst 130(5), 606-625 (2005). (Pubitemid 40685888)
17. Lindon JC, Holmes E, Nicholson JK. Metabonomics in pharmaceutical R & D. FEBS J. 274(5), 1140-1151 (2007).
18. Nordstorm A, Lewensohn R. Metabolomics: moving to the clinic. J. Neuroimmune Pharmacol. 5(1), 4-17 (2010).
19. Wen H, Yoo SS, Kang J et al. A new NMR-based metabolomics approach for the diagnosis of biliary tract cancer. Hepatol. 52(2), 228-233 (2010).
20. Lewis IA, Schommer SC, Markley JL. rNMR: open source software for identifying and quantifying metabolites in NMR spectra. Magn. Reson. Chem. 47(1), 123-126 (2009).
21. Giavalisco P, Kohl K, Hummel J, Bettina B, Willmitzer L. 13C isotope-labeled metabolomes allowing for improved compound annotation and relative quantification in liquid chromatography-mass spectrometry-based metabolomic research. Anal. Chem. 81, 6546-6551 (2009).
22. Brennan L. Personalised nutrition. Metabolomic applications in nutritional research. Proc. Nutr. Soc. 67(4), 404-408 (2008).
23. Coen M, Holmes E, Lindon JC, Nicholson JK. NMR-based metabolic profiling and metabonomic approaches to problems in molecular toxicology. Chem. Res. Toxicol. 21(1), 9-27 (2008). (Pubitemid 351219705)
24. Xiayan L, Legido-Quigley C. Advances in separation science applied to metabonomics. Electrophoresis 29(18), 3724-3736 (2008).
25. Goodacre R, Vaidyanathan S, Dunn WB, Harrigan GG, Kell DB. Metabolomics by numbers:acquiring and understanding global metabolite data. Trends Biotechnol. 22(5), 245-252 (2004). (Pubitemid 38515742)
26. Servais AC, Crommen J, Fillet M. Capillary electrophoresis-mass spectrometry, an attractive tool for drug bioanalysis and biomarker discovery. Electrophoresis 27(13), 2616-2629 (2006). (Pubitemid 44057515)
27. Xie G, Su M, Li P et al. Analysis of urinary metabolites for metabolomic study by pressurized CEC. Electrophoresis 28(23), 4459-4468 (2007). (Pubitemid 350259048)
28. O'Shaughnessy M, Konety B, Warlick C Prostate cancer screening: issues and controversies. Minn. Med. 93(8), 39-44 (2010).
29. Schorge JO, Modesitt SC, Coleman RL et al. SGO White Paper on ovarian cancer: etiology, screening and surveillance. Gynecol. Oncol. 119(1), 7-17 (2010).
30. Jha AK, Jha J, Bista R et al. A scenario of cervical carcinoma in a cancer hospital. JNMAJ Nepal Med. Assoc. 48(175), 199-202 (2009).
31. Arbyn M, Raifu AO, Weiderpass E, Bray F, Anttila A. Trends of cervical cancer mortality in the member states of the European Union. Eur. J. Cancer. 45(15), 2640-2648 (2009).
32. Kakehi Y, Hirao Y, Kim W et al. Bladder Cancer Working Group report. Jpn. J. Clin. Oncol. 40(Suppl. 1), 57-64 (2010).
33. Herman MP, Svatek RS, Lotan Y, Karakiewizc PI, Shariat SF. Urine-based biomarkers for the early detection and surveillance of non-muscle invasive bladder cancer. Minerva Urol. Nefrol. 60(4), 217-235 (2008).
34. Naito S, Tomita Y, Rha SY et al. Kidney Cancer Working Group report. Jpn. J. Clin. Oncol. 40(Suppl. 1), i51-i56 (2010).
35. Osl M, Dreiseitl S, Pfeifer B et al. A new rule-based algorithm for identifying metabolic markers in prostate cancer using tandem mass spectrometry. Bioinformatics 24(24), 2908-2914 (2008).
36. Goodacre R. Metabolomics of a superorganism. J. Nutr. 137(Suppl. 1), 259S-266S (2007). (Pubitemid 46070106)
37. Griffin JL, Shockcor JP. Metabolic profiles of cancer cells. Nat. Rev. Cancer. 4(7), 551-561 (2004). (Pubitemid 38868624)
38. Seidel A, Brunner S, Seidel P, Fritz GI, Herbarth O. Modified nucleosides: an accurate tumor marker for clinical diagnosis of cancer, early detection and therapy control. Br. J. Cancer 94(11), 1726-1733 (2006). (Pubitemid 43924939)
39. Szymańska E, Markuszewski MJ, Bodzioch K, Kaliszan R. Development and validation of urinary nucleosides and creatinine assay by capillary electrophoresis with solid-phase extraction. J. Pharm. Biomed. Anal. 44(5), 1118-1126 (2007). (Pubitemid 47239305)
40. Szymańska E, Markuszewski MJ, Markuszewski M, Kaliszan R. Altered levels of nucleoside metabolite profiles on urogenital tract cancer measured by capillary electrophoresis. J. Pharm. Biomed. Anal. 53(5), 1305-1312 (2010).
41. Theodorescu D, Wittke S, Ross MM et al. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol. 7(3), 230-240 (2006). (Pubitemid 43286453)
42. Odunsi K, Wollman RM, Ambrosone CB et al. Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics. Int. J. Cancer. 113(5), 782-788 (2005). (Pubitemid 40101260)
43. Jordan KW, Cheng LL. NMR-based metabolomics approach to target biomarkers for human prostate cancer. Expert Rev. Proteomics. 4(3), 389-400 (2007). (Pubitemid 46890076)
44. Serkova NJ, Gamito EJ, Jones RH et al. The metabolites citrate, myo-inositol, and spermine are potential age-independent markers of prostate cancer in human expressed prostatic secretions. Prostate 68(6), 620-628 (2008). (Pubitemid 351614640)
45. Mueller-Lisse UG, Scherr MK. Proton MR spectroscopy of the prostate. Eur. J. Radiol. 63(3), 351-360 (2007). (Pubitemid 47321931)
46. Lyng H, Sitter B, Bathen TF et al. Metabolic mapping by use of high-resolution magic angle spinning 1H MR spectroscopy for assessment of apoptosis in cervical carcinomas. BMC Cancer 7, 11 (2007).
47. Gao H, Dong B, Liu X et al. Metabonomic profiling of renal cell carcinoma: high resolution proton nuclear magnetic resonance spectroscopy of human serum with multivariate data analysis. Anal. Chim. Acta. 624(2), 269-277 (2008).
48. Kim K, Aronov P, Zakharkin SO et al. Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Mol. Cell Proteomics. 8(3), 558-570 (2009).
49. Issaq HJ, Nativ O, Waybright T et al. Detection of bladder cancer in human urine by metabolomic profiling using high performance liquid chromatography/mass spectrometry. J. Urol. 179(6), 2422-2426 (2008).
50. Guan W, Zhou M, Hampton CY et al. Ovarian cancer detection from metabolomic liquid chromatography/mass spectrometry data by support vector machines. BMC Bioinformatics 10, 259 (2009).
51. Avril N, Sassen S, Schmalfeldt B et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J. Clin. Oncol. 23(30), 7445-7453 (2005). (Pubitemid 46291806)
52. Mutch D, Markman M. A case report demonstrating unambiguous clinical utility of PET/CT scanning in recurrent ovarian cancer. Case Rep. Oncol. 2(2), 121-124 (2009).
53. Pucar D, Koutcher JA, Shah A et al. Preliminary assessment of magnetic resonance spectroscopic imaging in predicting treatment outcome in patients with prostate cancer at high risk for relapse. Clin. Prostate Cancer 3(3), 174-181 (2004). (Pubitemid 40051709)
54. Nordström A, Lewensohn R. Metabolomics: moving to the clinic. J. Neuroimmune Pharmacol. 5(1), 4-17 (2009).
55. Oldiges M, Lutz S, Pflug S et al. Metabolomics: current state and evolving methodologies and tools. Appl. Microbiol. Biotechnol. 76, 495-511 (2007). (Pubitemid 47283107)
56. Boros LG, Lerner MR. d-glucose profiles of serum, liver, pancreas, and DMBA-induced pancreatic tumors of rats. Pancreas 32, 337-343 (2005). (Pubitemid 41566882)
57. Weisberg E, Wright RD, Jiang J. Effects of PKC 412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity. Gastroenterology 131, 1734-1742 (2006). (Pubitemid 44958515)
58. Serkova NJ, Niemann CU. Pattern recognition and biomarker validation using quantitative 1H-NMR-based metabolomics. Expert Rev. Mol. Diagn. 6, 717-731 (2006). (Pubitemid 44525597)